

Europass Curriculum Vitae



Personal information

First name(s) / Surname(s) **VALENTINA FRANCO**

E-mail(s) valentina.franco@unipv.it

Nationality Italian

Gender Female

Occupational field **Scientific Research**

Work experience

Dates 2019 to date

Occupation or position held Senior Researcher, Department of Internal Medicine and Therapeutics, University of Pavia and IRCCS Mondino Foundation Neurological Institute, Pavia

Dates 2014 to 2018

Occupation or position held Adjunct Assistant Professor (temporary position), University of Pavia, Faculty of Medicine and Surgery (CdL Tecniche di Neurofisiopatologia, Modulo Farmacologia 2)

Dates August 2014 to 2018

Occupation or position held Pharmacologist at Clinical Trial Center, C. Mondino National Neurological Institute, Pavia, Italy

Main activities and responsibilities
Conduction of research focused primarily on the clinical pharmacology of antiepileptic drugs
Monitoring and auditing of study centres (ref. DM 15 November 2011)
Interim analysis and reporting of study results
e-CRF development
Medical writing

Dates January 2010 to July 2014

Occupation or position held Medical Advisor, Europe South East for the European Epilepsy Business Unit

Main activities and responsibilities
• Design and management of clinical trials in compliance with GCP
• Development of scientific documentation on specific products
• Training the Sales Force
• Managing relationships with KOLs
• Scientific updates
• Design and support marketing communication strategies
• Participation in national and international conferences

Type of business or sector Pharmaceuticals

Dates 2005 - 2009

Occupation or position held Postgraduate Research Fellow (Ph.D. programme, 3 years) / Postdoctoral Research Fellow (1 year: Nov 2008-Dec 2009)

Main activities and responsibilities
Conduction of research focused primarily on the clinical pharmacology of antiepileptic drugs, as part of a Ph.D. programme completed at the Department of Internal Medicine and Therapeutics, Faculty of

| | |
|--|---|
| | Medicine, University of Pavia .This included responsibility for the development and validation of HPLC-UV methods for the determination of antiepileptic drugs in biological fluids and the processing and interpretation of pharmacokinetic parameters from studies in experimental animals and humans. Other responsibilities included a contribution to the SOPHIE study ("Study of Outcome of Pharmacoresistance In Epilepsy"), an observational multicentre study supported by the Italian Medicines Agency and aimed at assessing adverse effects, efficacy outcomes, mood status, health-related quality of life and drug utilization/pharmaco-economic data in patients with refractory epilepsy. Work related to this study, which enrolled over 1,000 consecutive patients at 11 centres in Italy, included the development and testing of an electronic CRF and statistical database, monitoring and auditing of study centres, and the interim analysis and reporting of study results. |
| Name and address of employer | Department of Internal Medicine and Therapeutics, Faculty of Medicine, University of Pavia , Italy (tutor: Dr. Emilio Perucca, Professor of Clinical Pharmacology), Via Ferrata, 9, 27100 Pavia, Italy |
| Type of business or sector | Clinical Pharmacology / Neurology (academic) |
| Dates | 2015 |
| Title of qualification awarded | Specialization in Medical Pharmacology |
| Name and type of organisation providing education and training | University of Milan Milan, Italy |
| Dates | 2010 |
| Title of qualification awarded | Master degree in Regulatory Affairs (2 years) |
| Principal subjects / occupational skills covered | Regulatory Affairs |
| Name and type of organisation providing education and training | University of Pavia Pavia, Italy |
| Dates | 2008 |
| Title of qualification awarded | Ph.D in Pharmacological Sciences |
| Principal subjects / occupational skills covered | Clinical pharmacology (see above under "Work experience") |
| Name and type of organisation providing education and training | University of Pavia Pavia, Italy |
| Dates | 2005 |
| Title of qualification awarded | National certification to practice pharmacy |
| Name and type of organisation providing education and training | University of Pavia Pavia, Italy |
| Dates | 2004 |
| Title of qualification awarded | Bachelor in Medicinal Chemistry (CTF) |
| Principal subjects / occupational skills covered | Studies on photochemical reactivity of fluorinated antibacterial agents |
| Name and type of organisation providing education and training | University of Pavia Pavia, Italy |

Personal skills and competences

Mother tongue(s) **Italian**

Other language(s) **English**

Self-assessment
European level ()*

| Understanding | | Speaking | | Writing |
|---------------|---------|--------------------|-------------------|---------|
| Listening | Reading | Spoken interaction | Spoken production | |

(*) [Common European Framework of Reference \(CEF\) level](#)

Computer skills and competences

Microsoft Office
 Microsoft ChemDraw
 Software analytical instrumentation management (HPLC System "Shimadzu"; MS System "AB SCIEX")
 RevMan5
 SPSS
 Medline, EMBASE

Additional information

Prof. Emilio Perucca
 Department of Internal Medicine and Therapeutics, Faculty of Medicine, University of Pavia
 Via Ferrata, 9, 27100, Pavia
 e-mail: perucca@unipv.it

Annexes

ALEXANDRE V, FATTORE C, FRANCO V, PERUCCA E.
 Il BDI-II nello screening per la depressione in pazienti con epilessia: uno strumento utile per identificare una patologia sottostimata. *Items* 2006

FRANCO V, MAZZUCHELLI I, FATTORE C, MARCHISELLI R, GATTI G AND PERUCCA E.
 Stereoselective Determination of Vigabatrin Enantiomers in Human Plasma by High Performance Liquid Chromatography Using UV Detection. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2007; 854:63-7

MAZZUCHELLI I, FRANCO V, FATTORE C, MARCHISELLI R, PERUCCA E AND GATTI G.
 A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in human plasma. *Ther Drug Monit.* 2007; 29:319-24

MANENT JB, JORQUERA I, FRANCO V, BEN-ARI Y, PERUCCA E, REPRESA A.
 Antiepileptic drugs and brain maturation: Fetal exposure to lamotrigine generates cortical malformations in rats. *Epilepsy Res.* 2007; 78:131-9

FRANCO V, MAZZUCHELLI I, GATTI G, SPECCHIO LM, LA NEVE A, PAPANTONIO A, OZKAYNAKCI AE AND PERUCCA E.
 Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium. *Ther Drug Monit.* 2008; 30:544-7

MALERBA A, CANEVINI MP, CIAMPA C, FRANCO V, FRASSINE B, GALIMBERTI CA, GAMBARDELLA A, LA NEVE A, PELLACANI S, ROSATI E, TINUPER P, PERUCCA E.
 Patterns of drug utilization in patients with refractory epilepsy at tertiary referral centres in Italy. The SOPHIE study. *Epilepsia*, 50(Suppl. 10):1-182, 2009

ALEXANDRE V JR, DE FAZIO S, FATTORE C, FRANCO V, FRASSINE B, LA BRIOLA F, LADOGANA M, LA NEVE A, LICCHETTA L, PAPANTONIO A, PELLACANI S, ROSATI E, STRIANO P. AND PERUCCA E.
 The impact of adverse effects on health-related quality of life in patients with pharmacoresistant epilepsy: the SOPHIE study (study of pharmacoresistance in epilepsy). *Epilepsia*, 50(Suppl. 4): 2-262, 2009

ALEXANDRE V, CAPOVILLA G, FATTORE C, FRANCO V., GAMBARDELLA A, GUERRINI R, LA BRIOLA F, LADOGANA M, ROSATI E, SPECCHIO LM, STRIANO S, PERUCCA ON BEHALF OF THE SOPHIE STUDY GROUP.

Characteristics of a Large Population of Patients with Refractory Epilepsy Attending Tertiary Referral Centres in Italy. *Epilepsia*. 2010; 51:921-5

TOZZI R, FATTORE C, GALIMBERTI CA, FRANCO V., GATTI G, MALERBA A, MAZZUCHELLI I, MESSINA S, CANEVINI MP, LA BRIOLA F.

Italian version of the adverse events profile questionnaire in patients with epilepsy: translation, reliability and stability. *Epilepsia*, 51(suppl. 4):1-189, 2010

CANEVINI MP, DE SARRO G, GALIMBERTI CA, GATTI G, LICCHETTA L, MALERBA A, MUSCAS G, LA NEVE A, STRIANO P, PERUCCA E, BARUZZI A, BONIZZONI E, FATTORE C, FRANCO V., MARZANATTI M, MAZZUCHELLI I ET AL.

Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. *Epilepsia*. 2010; 51(5): 797-804.

MAZZUCHELLI I, RAPETTI M, FATTORE C, FRANCO V., GATTI G, PERUCCA E.
Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva. *Analytical & Bioanalytical Chemistry*. 2011; 401:1013-21

FRANCO V., CREMA F, IUDICE A, ZACCARA G, GRILLO E
Novel Treatment Options for Epilepsy: Focus on Perampanel. *Pharmacological Research* 2013; 1;70:35-40

FRANCO V., IUDICE A, GRILLO E, CITRARO R, DE SARRO G, RUSSO E. Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures. *Expert Opin Pharmacother* 2014;15(5): 637-44

CITRARO R, AIELLO R, FRANCO V., DE SARRO G, RUSSO E. Targeting α -amino-3-hydroxyl-5-methyl-4 isoxazole-propionate receptors in epilepsy. *Expert Opin Ther Targets*. 2014;18:319-34

RUSSO E, COPETTI M, FRANCO V., GRILLO E, ZACCARA G. An overall and dose-response meta-analysis of efficacy of newer generation antiepileptic drugs in the treatment of secondarily generalized tonic-clonic seizures. *Epilepsia* 2014; 55,s2: 1-291 (Best Poster Presentation at the 11th European Congress on Epileptology, Stockholm 2014)

FRANCO V., RUSSO E. Glutammato ed epilessia. Dal razionale fisiopatologico allo sviluppo di nuovi farmaci attraverso il meccanismo d'azione. *La Neurologia Italiana* 01/2014; 4:21-4

FRANCO V., CANEVINI MP, CAPOVILLA G, DE SARRO G, GALIMBERTI CA, GATTI G, GUERRINI R, LA NEVE A, ROSATI E, SPECCHIO LM, STRIANO S, TINUPER P, PERUCCA E. Off-Label Prescribing of Antiepileptic Drugs in Pharmacoresistant Epilepsy: A Cross-Sectional Drug Utilization Study of Tertiary Care Centers in Italy. *CNS Drugs*. 2014. 28:939-49

ZACCARA G, GIOVANNELLI F, FRANCO V., CINCOTTA M, TRAMACERE L, VERROTTI A.
Adverse events, placebo and nocebo effects in placebo-treated paediatric patients with refractory focal epilepsies. Analysis of double-blind studies. *Epilepsy Research* 2014; 108:1685-93

FRANCO V., PERUCCA E. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. *Expert Opin Drug Metab Toxicol*. 2015;11:1269-79

ROMIGI A, FEMIA EA, FATTORE C, VITRANI G, DI GENNARO G, FRANCO V. Zonisamide in the management of epilepsy in the elderly. *Clin Interv Aging*. 2015 Jun 8;10:931-7

FRANCO V., PERUCCA E. The pharmacogenomics of epilepsy. *Expert Rev Neurother*. 2015 Oct;15:1161-70

VERROTTI A, PREZIOSO G, DI SABATINO F, FRANCO V., CHIARELLI F, ZACCARA G. The adverse event profile of levetiracetam: A meta-analysis on children and adults. *Seizure*. 2015 Sep;31:49-55

FRANCO V, FRENCH JA, PERUCCA E. Challenges in the clinical development of new antiepileptic drugs. *Pharmacol Res.* 2016;103:95-104

ZACCARA G, GIOVANNELLI F, GIORGI FS, FRANCO V, GASPARINI S. Analysis of nocebo effects of antiepileptic drugs across different conditions. *J Neurol.* 2016; 263:1274-9

FRANCO V, MARCHISELLI R, FATTORE C, TARTARA E, DE SARRO G, RUSSO E AND PERUCCA E. Development and Validation of an HPLC-UV Assay for the Therapeutic Monitoring of the New Antiepileptic Drug Perampanel in Human Plasma. *Therapeutic Drug Monitoring.* 2016; 38:744-750

CITRARO R, LEO A, FRANCO V, MARCHISELLI R, PERUCCA E, DE SARRO G AND RUSSO E. Perampanel effects in the WAG/Rij rat model of epileptogenesis, absence epilepsy and comorbid depressive-like behavior. *Epilepsia.* 2017; 58:231-238

ZACCARA G, GIOVANNELLI F, GIORGI FS, FRANCO V, GASPARINI S, BENEDETTO U. Tolerability of new antiepileptic drugs: a network meta-analysis. *Eur J Clin Pharmacol.* 2017; 73:811-817.

ZACCARA G, GIOVANNELLI F, GIORGI FS, FRANCO V, GASPARINI S, AND MANDÒ TACCONI F. Do antiepileptic drugs increase the risk of infectious diseases? A meta-analysis of placebo-controlled studies. *Br J Clin Pharmacol.* 2017; 83:1873-1879.

PULITANO P, FRANCO V, MECARELLI O, BRIENZA M, DAVASSI C, RUSSO E. Effects of eslicarbazepine acetate on lipid profile and sodium levels in patients with epilepsy. *Seizure.* 2017;53:1-3

ROMIGI A, VITRANI G, GIUDICE TL, CENTONZE D, FRANCO V. Profile of pitolisant in the management of narcolepsy: Design, development, and place in therapy. *Drug Design, Development and Therapy.* 2018; 12: 2665–2675

GAGLIARDI S, FRANCO V, SORRENTINO S, ZUCCA S, PANDINI C, ROTA P, BERNUZZI S, COSTA A, SINFORIANI E, PANSARASA O, CASHMAN JR, CEREDA C. Curcumin and novel synthetic analogs in cell-based studies of Alzheimer's disease. *Frontiers in Pharmacology.* 2018; 9: 1404

FRANCO V, BARUFFI K, GATTI G, MARCHISELLI R, FATTORE C, CANEVINI MP, CREMA F, PERUCCA E. A simple and rapid HPLC-UV method for the determination of retigabine in human plasma. *Biomed Chromatogr.* 2018; 32:e4168.

ROMIGI A, FRANCO V, PLACIDI F, LIGUORI C, RASTELLI E, VITRANI G, CENTONZE G, MASSA R. Comparative Sleep Disturbances in Myotonic Dystrophy Types 1 and 2. *Current Neurology and Neuroscience Reports.* 2018; 18(12): 102

FRANCO V, PERUCCA E. Pharmacological and therapeutic properties of cannabidiol for epilepsy. *Drugs.* 2019; 79(13): 1435-1454

FRANCO V, BARUFFI K, MARCHISELLI R, CREMA F, FATTORE C, ROMIGI A, DE GIORGI V, TARTARA E, ELIA M, D'AVOLIO A, PERUCCA E. Determination of perampanel in dried plasmaspots: applicability to therapeutic drug monitoring. *Therapeutic drug monitoring.* 2020; 42: 309-314

LA ROCCA P, ROTA P, PICCOLI M, CIRILLO F, GHIROLDI A, FRANCO V, ALLEVI P, ANASTASIA L. 2 β -3,4-Unsaturated sialic acid derivatives: Synthesis optimization, and biological evaluation as Newcastle disease virus hemagglutinin-neuraminidase inhibitors. *Bioorganic and Medicinal Chemistry.* 2020;28:115563

FRANCO V, GATTI G, MAZZUCHELLI I, MARCHISELLI R, FATTOREC, ROTA P, GALIMBERTI CA, CAPOVILLA G, BECCARIA F, DE GIORGIS V, JOHANNESSEN LANDMARK C, AND EMILIO PERUCCA E. Relationship between saliva and plasma rufinamide concentrations in patients with epilepsy. *Epilepsia* 2020;61:e79-e84

FRANCO V, CANEVINI MP, DE SARRO G, FATTORE C, FEDELE G, GALIMBERTI CA, GATTI G, LA NEVE A, ROSATI E, SPECCHIO LM, STRIANO S, TINUPER P AND PERUCCA E, ON BEHALF OF THE SOPHIE STUDY GROUP. Does screening for adverse effects improve health outcomes in epilepsy? A randomized trial. *Neurology* 2020;95:e239-e246

FRANCO V, GERSHKOVICH P, PERUCCA E, BIALER M. The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. *Clinical Pharmacokinetics*. 2020; 59(12): 1493-1500

ROTA P, LA ROCCA P, FRANCO V, ALLEVI P. Straightforward access to 2,3- and 3,4-unsaturated derivatives of N-glycolylneuraminic acid. *Tetrahedron*. 2020; 76(49): 131699

ODI R, FRANCO V, PERUCCA E, BIALER M. Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe. *Epilepsia*, 2021; 62(2): 285–302

FRANCO V, BIALER M, PERUCCA E. Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. *Neuropharmacology*. 2021; 185: 108442

FRANCO V, PERUCCA E. Author Response: Does Screening for Adverse Effects Improve Health Outcomes in Epilepsy? A Randomized Trial. *Neurology*. 2021; 96(13): 639

FRANCO V, BARBIERI MA, CUTRONEO PM, ARENA I, CICALA G, MARCHIONE P, SPINA E, PERUCCA E. Pediatric adverse reactions to antiseizure medications – An analysis of data from the Italian spontaneous reporting system (2001–2019). *Epilepsy and Behavior*. 2021; 119: 107989

FRANCO V, PALMISANI M, MARCHISELLI R, CREMA F, FATTORE C, DE GIORGIS V, VARESIO C, ROTA P, DIBARI VF, PERUCCA E. On-Line Solid Phase Extraction High Performance Liquid Chromatography Method Coupled With Tandem Mass Spectrometry for the Therapeutic Monitoring of Cannabidiol and 7-Hydroxy-cannabidiol in Human Serum and Saliva. *Frontiers in Pharmacology*. 2022; 13: 915004

BARBIERI MA, PERUCCA E, SPINA E, ROTA P, FRANCO V. Cenobamate: A Review of its Pharmacological Properties, Clinical Efficacy and Tolerability Profile in the Treatment of Epilepsy. *CNS and Neurological Disorders - Drug Targets*. 2023; 22(3): 394–403

VARESIO C, FRANCO V, PASCA L, CELARIO M, FATTORE C, FEDELE G, ROTA P, PALMISANI M, DE GIORGIS V. Melatonin versus Sleep Deprivation for Sleep Induction in Nap Electroencephalography: Protocol for a Prospective Randomized Crossover Trial in Children and Young Adults with Epilepsy. *Metabolites*. *ACS Infectious Diseases*. 2023; 13(3), 383

ROTA P, LA ROCCA P, BONFANTE F, PAGLIARI M, PICCOLI M, CIRILLIO F, GHIROLDI A, FRANCO V, PAPPONE C, ALLEVI P, ANASTASIA L. Design, Synthesis, and Antiviral Evaluation of Sialic Acid Derivatives as Inhibitors of Newcastle Disease Virus Hemagglutinin-Neuraminidase: A Translational Study on Human Parainfluenza Viruses. *ACS Infectious Diseases*. 2023; 9(3): 617–630

GRECO R, FRANCAVILLA M, DEMARTINI C, ZANABONI AM, SODERGREN MH, FACCHETTI S, PACCHETTI B, PALMISANI M, FRANCO V, TASSORELLI C. Characterization of the biochemical and behavioral effects of cannabidiol: implications for migraine. *Journal of Headache and Pain*. 2023; 24(1): 48

ZACCARA G, FRANCO V. Pharmacokinetic Interactions Between Antiseizure and Psychiatric Medications. *Curr Neuropharmacol*. 2023;21(8):1666-1690.

GRECO R, FRANCAVILLA M, DEMARTINI C, ZANABONI AM, FACCHETTI S, PALMISANI M, FRANCO V, TASSORELLI C. Activity of FAAH-Inhibitor JZP327A in an Experimental Rat Model of Migraine. *Int J Mol Sci*. 2023 Jun 14;24(12):10102.

JOHANNESSEN LANDMARK C, EYAL S, BURNS ML, FRANCO V, JOHANNESSEN SI. Pharmacological aspects of antiseizure medications: From basic mechanisms to clinical considerations of drug interactions and use of therapeutic drug monitoring. *Epileptic Disord.* 2023 Aug;25(4):454-471.

PALMISANI M, TARTARA E, JOHANNESSEN LANDMARK C, CREMA F, DE GIORGIS V, VAREGIO C, FATTORE C, ROTA P, RUSSO E, FRANCO V. Therapeutic Salivary Monitoring of Perampanel in Patients with Epilepsy Using a Volumetric Absorptive Microsampling Technique. *Pharmaceutics.* 2023 Jul 27;15(8):2030.

ROTA P, LA ROCCA P, BONFANTE F, PAGLIARI M, CIRILLO F, PICCOLI M, GHIROLDI A, FRANCO V, PAPPONE C, ALLEVI P, ANASTASIA L. Interplay of Modified Sialic Acid Inhibitors and the Human Parainfluenza Virus 1 Hemagglutinin-Neuraminidase Active Site. *ACS Med Chem Lett.* 2023 Sep 26;14(10):1383-1388.

COLUCCI F, AVENALI M, DE MICCO R, FUSAR POLI M, CERRI S, STANZIANO M, BACILA A, CUCONATO G, FRANCO V, FRANCIOTTA D, GHEZZI C, GASTALDI M, ELIA AE, ROMITO L, DEVIGILI G, LETA V, GARAVAGLIA B, GOLFRÉ ANDREASI N, CAZZANIGA F, REALE C, GALANDRA C, GERMANI G, MITROTTI P, ONGARI G, PALMIERI I, PICASCIA M, PICHIECCHIO A, VERRI M, ESPOSITO F, CIRILLO M, DI NARDO F, ALOISIO S, SICILIANO M, PRIONI S, AMAMI P, PIACENTINI S, BRUZZONE MG, GRISOLI M, MODA F, ELEOPRA R, TESSITORE A, VALENTE EM, CILIA R. Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson's disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol. *BMJ Neurol Open.* 2023 Nov 24;5(2):e000535.

SHAWAHNA R, SABA'ANEH H, DARAGHMEH A, QASSARWI Y, FRANCO V, DECLÈVES X. Solubility of lamotrigine in age-specific biorelevant media that simulated the fasted- and fed-conditions of the gastric and intestinal environments in pediatrics and adults: implications for traditional, re-formulated, modified, and new oral formulations. *BMC Biotechnol.* 2023 Sep 8;23(1):36.

GAROFOLI F, FRANCO V, ACCORSI P, ALBERTINI R, ANGELINI M, ASTEGGIANO C, AVERSA S, BALLANTE E, BORGATTI R, CABINI RF, CAPORALI C, CHIAPPARINI L, COCIGLIO S, FAZZI E, LONGO S, MALERBA L, MATERIA V, MAZZOCCHI L, NABONI C, PALMISANI M, PICHIECCHIO A, PINELLI L, PISONI C, PREDAL L, RIBOLI A, RISSO FM, RIZZO V, ROGNONE E, SIMONCELLI AM, VILLANI P, TZIALLA C, GHIRARDELLO S, ORCESI S. Fate of melatonin orally administered in preterm newborns: Antioxidant performance and basis for neuroprotection. *J Pineal Res.* 2024 Jan;76(1):e12932. doi: 10.1111/jpi.12932. Epub 2023 Dec 18.

Bibliometric indicators

H index= 20
Citation Number=1156

In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document.